Menquadfi (Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi)

The vaccine contains capsular polysaccharide from serogroup C linked to tetanus toxoid, converting the polysaccharide into a T‑cell‑dependent antigen. This conjugation activates helper T cells, leading to strong B‑cell responses and the production of high‑affinity anti‑capsular antibodies that neutralize the bacteria and prevent invasive disease.

The dose of Menquadfi is determined by the prescribing healthcare professional based on age, risk factors and local immunization schedules. Typically a single intramuscular injection is given, with possible booster doses as recommended by public‑health authorities. Exact dosing and timing should be confirmed with the prescriber.

Safety data for Menquadfi in pregnancy are limited, and the vaccine should only be administered after a risk‑benefit assessment by a qualified healthcare provider. Breastfeeding is not a contraindication, but mothers should discuss any concerns with their clinician to ensure appropriate protection for both mother and infant.

To place an order, submit an enquiry on the Menquadfi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Menquadfi is a serogroup C conjugate vaccine, offering T‑cell‑dependent immunity and long‑lasting protection, whereas polysaccharide‑only vaccines may induce a shorter‑duration response and are less effective in young children. Compared with quadrivalent conjugate vaccines that cover serogroups A, C, W and Y, Menquadfi targets only serogroup C, making it suitable for regions where that serogroup predominates.

Menquadfi must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to administration, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration before use.

Menquadfi is given as a single intramuscular injection, usually into the deltoid muscle of the upper arm. The injection should be performed by a qualified healthcare professional using aseptic technique. The site may be observed for a short period after vaccination to monitor for immediate adverse reactions.

The most serious adverse events associated with Menquadfi are rare but include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and neurologic events like seizures. Recipients should be observed for at least 15 minutes after injection, and any signs of severe hypersensitivity or neurological symptoms should prompt immediate medical evaluation.

Menquadfi is contraindicated in individuals with a known hypersensitivity to tetanus toxoid, any component of the vaccine, or a previous severe allergic reaction to a meningococcal conjugate vaccine. Persons with acute moderate or severe illness should defer vaccination until recovery, and those with uncertain immune status should consult a healthcare professional before receiving the vaccine.